-
Dec 30, 2024 | 
bmj.com | William B. Feldman |Samy Suissa |Aaron S. Kesselheim |Jerry Avorn
Research BMJ 2024; 387 doi: https://doi.org/10.1136/bmj-2024-080409 Cite this as: BMJ 2024;387:e080409 Linked Editorial Environmentally friendly inhaler regimens for COPD William B Feldman, assistant professor1 2 3, Samy Suissa, professor4, Aaron S Kesselheim, professor1 3, Jerry Avorn, professor1 3, Massimiliano Russo, assistant professor5, Sebastian Schneeweiss, professor1 3, Shirley V Wang, associate professor1 3 1Division of Pharmacoepidemiology and Pharmacoeconomics, Department of...
-
Nov 25, 2024 | 
jamanetwork.com | Olivier J. Wouters |Matthew Vogel |William B. Feldman |Aaron S. Kesselheim
Differential Legal Protections for Biologics vs Small-Molecule Drugs in the US Abstract Importance Biologics approved by the US Food and Drug Administration (FDA) receive 12 years of guaranteed protection from biosimilar competition compared with 5 years of protection from generic competition for new small-molecule drugs.
-
Sep 18, 2024 | 
jamanetwork.com | Aaron S. Kesselheim |William B. Feldman |Arash Mostaghimi |BSc Hons
Estimating Costs in Beremagene Geperpavec for Dystrophic Epidermolysis Bullosa—Reply Estimated Spending on Beremagene Geperpavec for Dystrophic Epidermolysis Bullosa Adam J. N. Raymakers, PhD; Aaron S. Kesselheim, MD, JD, MPH; Arash Mostaghimi, MD, MPA, MPH; William B. Feldman, MD, DPhil, MPH Estimating Costs in Beremagene Geperpavec for Dystrophic Epidermolysis Bullosa Michelle K. Y.
-
Sep 17, 2024 | 
onlinelibrary.wiley.com | Kevin A. Schulman |Aaron S. Kesselheim |William B. Feldman |Iselin Dahlen Syversen
Policy Points Health care systems around the world rely on a range of methods to ensure the affordability of prescription drugs, including negotiating prices soon after drug approval and relying on formal clinical assessments that compare newly approved therapies with existing alternatives. The negotiation framework established under the Inflation Reduction Act is far more limited than other frameworks explored in this study.
-
Sep 5, 2024 | 
jamanetwork.com | Liam Bendicksen |Aaron S. Kesselheim |William B. Feldman
Seeking a Better Paper Trail of Federal Research Funding The US federal government invests billions of dollars annually in pharmaceutical research and development.
-
Aug 13, 2024 | 
onlinelibrary.wiley.com | Priyanka Anand |Elvira D'Andrea |William B. Feldman |Shirley Wang
Conflicts of Interest Kueiyu Joshua Lin, Priyanka Anand, Jun Liu, Shirley V. Wang, Gregory Brill, and Elyse DiCesare have no conflicts of interest to disclose. Elvira D'Andrea is currently employed at and owns shares in AbbVie Inc. Outside of the current work, Dr. William Feldman serves as a consultant for Alosa Health and as an expert witness in litigation against inhaler manufacturers. He also served as a consultant for Aetion.
-
Jul 19, 2024 | 
jamanetwork.com | S. Tu |William B. Feldman
Introduction
Pharmaceutical manufacturers obtain patents at various points leading up to and following US Food and Drug Administration (FDA) approval of new drugs.
-
Jul 18, 2024 | 
jamanetwork.com | Katsiaryna Bykov |William B. Feldman |Krista F Huybrechts |Catherine Hwang
Key PointsQuestion How did use of and liver function tests (LFTs) for ambrisentan vs bosentan change after the boxed hepatotoxicity warning and LFT requirement under the risk evaluation and mitigation strategy (REMS) were removed for ambrisentan but not bosentan?
-
Jul 5, 2024 | 
onlinelibrary.wiley.com | Junyi Wang |Ameet Sarpatwari |Aaron S. Kesselheim |William B. Feldman
CONFLICT OF INTEREST STATEMENT William B. Feldman reports serving as a consultant for Alosa Health and as an expert witness in litigation against inhaler manufacturers. Supporting Information Filename Description pbc31158-sup-0001-SuppMat.docx34.9 KB Supporting Information REFERENCES 1 Medicare Payment Advisory Commission. Report to Congress: overview of the 340B Drug Pricing Program. MEdpAC; May 2015. Accessed September 20, 2023.
-
Jun 4, 2024 | 
dialnet.unirioja.es | Aaron S. Kesselheim |Arash Mostaghimi |William B. Feldman |Adam J. N
Estimated Spending on Beremagene Geperpavec for Dystrophic Epidermolysis BullosaAutores: Adam J. N. Raymakers, Aaron S. Kesselheim, Arash Mostaghimi, William B. FeldmanLocalización: JAMA Dermatology, ISSN 2168-6068, Vol. 160, Nº. 3, 2024, págs. 297-302Idioma: inglésEnlacesTexto completoResumenNew gene therapies can offer substantial benefits to patients, particularly those with rare diseases who have few therapeutic options.
